Navigation Links
NeuroCog Trials Appoints Industry Executive Michael Hufford, Ph.D. to Chief Operating Officer

DURHAM, N.C., Nov. 4, 2011 /PRNewswire/ -- NeuroCog Trials, Inc. today announced the appointment of Michael R. Hufford, Ph.D. to the position of Chief Operating Officer.  In this newly created position, Dr. Hufford will assume responsibility for the continued growth and expansion of NeuroCog Trials' business, research and development, and operations.

"The investment in research and development for pro-cognitive therapies across a wide variety of therapeutic areas has never been stronger.  As NeuroCog Trials continues to grow to meet these needs, we decided that it was time to bring someone on board with a proven track record of success on both the vendor and sponsor side of clinical research," said Richard Keefe, Ph.D., Founder and Chief Executive Officer at NeuroCog Trials. "We are delighted to have Dr. Hufford bring the wealth of his experience in industry, academia and entrepreneurship to NeuroCog Trials.  His role at NeuroCog represents a real advance for us in our ability to provide key services for increasingly larger trials across a broad range of CNS and other therapeutic areas."

Dr. Hufford brings to the company more than 14 years of experience in clinical research and drug development.  Prior to joining NeuroCog Trials, he was Vice President of Clinical Development at Cypress Bioscience, where he was responsible for drug and medical device development for multiple CNS programs.  Before joining Cypress, he worked at Amylin Pharmaceuticals, leading drug development teams focused on orphan drug development for rare metabolic diseases, combination peptide and protein therapies for obesity, and helped to spinout and was on the board of Psylin Neurosciences.  Between 2000 and 2005, Dr. Hufford was Vice President of Scientific Affairs at invivodata, inc., an electronic patient-reported outcomes company.  Prior to that, he was an Assistant Professor of Clinical Psychology at the University of Montana.  Dr. Hufford received his B.A. with Distinction in psychology from Purdue University, and his M.S. and Ph.D. in clinical psychology from the University of Pittsburgh.  Subsequently, he was a Clinical and Research Fellow in Department of Psychiatry at Harvard Medical School at the McLean Hospital.  Dr. Hufford has more than 90 scientific publications and presentations, with multiple issued and pending patents.

About NeuroCog Trials

NeuroCog Trials Inc. is the leading cognition services company for the pharmaceutical industry.  For more than 10 years, NeuroCog Trials has provided consulting, site screening, rater training and certification, and data review services to more than 50 clinical trials in over 25 countries.  NeuroCog Trials has certified more than 4,000 neurocognitive testers and assured data quality for over 50,000 assessments across a variety of therapeutic areas, including schizophrenia, Alzheimer's disease, major depressive disorder, bipolar disorder and brain cancer.  Our mission is to facilitate the development of novel therapies to enhance cognition.  We bring to all of our work deep expertise, strategic innovation, and an unwavering commitment to research excellence.

For more information on NeuroCog Trials, its services, and licensing inquiries for its exclusive neuropsychological and functional capacity assessment batteries, please see

Richard Keefe, Ph.D.
Founder & CEO
NeuroCog Trials
(919) 401-4642

SOURCE NeuroCog Trials, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Data From REMEDEE Trial Featuring OrbusNeichs Combo™ Dual Therapy Stent to be Presented in Late Breaking Clinical Trials and First Report Investigations Session at TCT 2011
2. CTRI Confirms Leading Indian CRO Supports Majority of Hemophilia Trials in India
3. QIAGEN to Develop New Companion Diagnostic for Compound in Clinical Trials for Blood Cancers
4. Kibow Biotech, Inc. Secures $2.4 Million Towards Its Human Clinical Trials by Continued Veterinary Licensing Agreement
5. Middle East to be the Future in Clincial Trials
6. Glenmark Initiates Phase IIb Human Trials Globally for its Novel Molecule Revamilast
7. Start of in-Patient Clinical Trials With NT-KO-003, the First Neuroprotective Drug for Multiple Sclerosis Without Immunosuppressive Effects
8. Family Foundation of Business Leader Invests $4.55 Million in Northwest Biotherapeutics for Promising Clinical Trials in the US and Europe
9. Drug Dropout in Clinical Trials Is at Unsustainable Levels, According to Thomson Reuters, CMR International
10. ERA-EDTA Congress 2011: Late Breaking Clinical Trials I
11. ACT Announces First Patients Enrolled in Two Clinical Trials Using Embryonic Stem Cells to Treat Stargardts Disease and Dry Age-Related Macular Degeneration
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... Cancer experts from Austria, Hungary, ... be a new and helpful biomarker for malignant pleural mesothelioma. Surviving Mesothelioma has ... it now. , Biomarkers are components in the blood, tissue or body ...
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf K. Hoffmann, former senior ... the University of North Carolina Kenan-Flagler Business School effective June 27. ... Kenan-Flagler, with a focus on the school’s international efforts, leading classes and participating ...
(Date:6/24/2016)... discussions on a range of subjects including policies, debt and ... Poloz. Speaking at a lecture to the Canadian ... to the country,s inflation target, which is set by both ... "In certain areas there needs to be ... why not sit down and address strategy together?" ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica delle Marche ... with peritoneal or pleural mesothelioma. Their findings are the subject of a new article ... Diagnostic biomarkers are signposts in the blood, lung fluid or tissue of mesothelioma patients ...
Breaking Biology Technology:
(Date:5/9/2016)... -- Elevay is currently known as the ... high net worth professionals seeking travel for work   ... there is still no substitute for a face-to-face meeting. ... deal with a firm handshake. This is why wealthy ... citizenship via investment programs like those offered by the ...
(Date:4/26/2016)... LONDON , April 26, 2016 ... a product subsidiary of Infosys (NYSE: ... to integrate the Onegini mobile security platform with ... ) The integration will ... to access and transact across channels. Using this ...
(Date:4/15/2016)... DUBLIN , April 15, 2016 ... of the,  "Global Gait Biometrics Market 2016-2020,"  report ... ) , ,The global gait ... CAGR of 13.98% during the period 2016-2020. ... movement angles, which can be used to compute ...
Breaking Biology News(10 mins):